Accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) treated with STI-571 (Gleevec): Peripheral blood (PB) and bone marrow (BM) findings

被引：0
|
作者：
Frater, JL [1 ]
Tallman, MS [1 ]
Variakojis, D [1 ]
Boehlke, L [1 ]
Peterson, LC [1 ]
机构：
[1] Northwestern Univ, Sch Med, Chicago, IL USA
来源：
LABORATORY INVESTIGATION | 2002年 / 82卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1006
引用
收藏
页码：241A / 241A
页数：1
相关论文
共 50 条
  • [1] Accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) treated with STI-571 (Gleevec): Peripheral blood (PB) and bone marrow (BM) findings
    Frater, JL
    Tallman, MS
    Variakojis, D
    Boehlke, L
    Peterson, LC
    MODERN PATHOLOGY, 2002, 15 (01) : 241A - 241A
  • [2] Importance of bone marrow biopsy in evaluating the responses to STI-571 in accelerated and blast phases of chronic myeloid leukemia (CML).
    Silver, RT
    Chadburn, A
    Feldman, E
    Schuster, M
    Godwin, J
    Berk, G
    Rosamilia, M
    BLOOD, 2000, 96 (11) : 257B - 257B
  • [3] Morphologic findings in peripheral blood and bone marrow of STI571-treated chronic myelogenous leukemia patients.
    Launder, TM
    Druker, BJ
    Mauro, MJ
    O'Dwyer, ME
    Resta, D
    Braziel, RM
    BLOOD, 2000, 96 (11) : 735A - 735A
  • [4] The clinical course of thrombocytopenia in patients treated with STI-571 (IMATINIB) for accelerated phase chronic myelogenous leukemia.
    van Deventer, HW
    Hall, MD
    Mitchell, BS
    Hogan, CM
    Lehman, MJ
    Bhagat, RK
    Berkowitz, LR
    Dunphy, CH
    Orlowski, RZ
    Stinchcombe, TE
    Smith, JS
    Powderly, JD
    Rao, KW
    Koehler, JA
    Nashed, A
    Shea, TC
    BLOOD, 2001, 98 (11) : 139A - 139A
  • [5] Safety and tolerability of STI-571 in patients with Ph plus chronic myeloid leukemia in accelerated phase (CML-AP) previously autotransplanted
    Boqué, C
    Encuentra, M
    Peralta, T
    Sala, O
    Moreno, C
    Petit, J
    Sarrà, J
    Grañena, A
    BONE MARROW TRANSPLANTATION, 2002, 29 : S35 - S35
  • [6] Bone marrow biopsy (BM) morphology in patients with chronic myeloid leukemia (CML) treated with STI571
    Chiu, A
    Silver, R
    Rosamillia, M
    Chadburn, A
    MODERN PATHOLOGY, 2001, 14 (01) : 159A - 159A
  • [7] Bone marrow biopsy (BM) morphology in patients with chronic myeloid leukemia (CML) treated with STI571
    Chiu, A
    Silver, R
    Rosamillia, M
    Chadburn, A
    LABORATORY INVESTIGATION, 2001, 81 (01) : 159A - 159A
  • [8] Gleevec/Glivec (imatinib mesylate, STI-571) in patients with chronic myeloid leukemia (CML) in myeloid blast crisis: Updated results of a phase II study.
    Sawyers, CL
    Hochhaus, A
    Feldman, E
    Goldman, JM
    Miller, C
    Ottman, OG
    Schiffer, CA
    Talpaz, M
    Guilhot, F
    Niederwieser, D
    Ben-Am, M
    Gathmann, I
    Ford, J
    Druker, BJ
    BLOOD, 2001, 98 (11) : 845A - 845A
  • [9] Safety and efficacy of STI-571 (Gleevec™) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation.
    Beck, J
    Reifenrath, C
    Hess, GR
    Corsetti, MT
    Kreil, S
    Meinhardt, P
    Beltrami, G
    Schuch, B
    Gschaidmeier, H
    Hehlmann, R
    Hochhaus, A
    Carella, A
    Huber, C
    Fischer, T
    BLOOD, 2001, 98 (11) : 140A - 140A
  • [10] Correlation of different responses to imatinib on survival of patients (pts) with chronic myelogenous leukemia (CML) in accelerated (AP) and blast phase (BP).
    Aoki, E
    Kantarjian, H
    O'Brien, S
    Rios, MB
    Ravandi, F
    Verstovsek, S
    Garcia-Manero, G
    Shan, JQ
    Cortes, J
    BLOOD, 2005, 106 (11) : 321A - 321A
12345